Applicant Serial Number

: Or et al. : 10/007,235

Filed Page : October 22, 2001 : 2

## Amendments to the claims:

1. (Currently Amended) A compound of formula:

$$R^{1}$$
 $A$ 
 $N$ 
 $OH$ 
 $D$ 
 $E$ 
 $R^{2}$ 
 $R^{1}$ 
 $A$ 
 $N$ 
 $H$ 
 $OH$ 
 $D$ 
 $E$ 

wherein:

 $R^1$  is chosen from the group consisting of  $C_1$ – $C_{20}$  alkyl, substituted  $C_1$ – $C_{20}$  alkyl, aryl, alkylaryl, substituted alkylaryl,  $C_3$ – $C_{10}$  oxaalkyl, aryloxy, substituted aryl, heterocyclyl and substituted heterocyclyl;

 $R^2$  is chosen from the group consisting of  $C_1$ – $C_{10}$  hydrocarbon, and substituted aryland heterocyclyl;

Applicant Serial Number : Or et al. : 10/007,235

Filed

: October 22, 2001

Page :

A is chosen from the group consisting of a direct bond,  $-SO_2$ -,  $NHSO_2$ -,  $-SO_2NHC(O)$ -,

n, wherein r $\rightarrow$  designates the point of attachment of R<sup>1</sup> and n $\rightarrow$  designates the point of attachment to N;



is <u>phenyl</u> monocyclic, bicyclic or tricyclic aryl or heteroaryl containing from 0 to 3 substituents chosen from lower alkyl, lower alkoxy, lower alkylthio, hydroxy, mercapto, cyano, carboxy, lower alkoxycarbonyl, (lower alkoxycarbonyl)lower alkoxy, lower alkylaminocarbonyl, amino, lower alkylamino, di(lower alkyl)amino, nitro, halo and haloalkyl;

R<sup>5</sup> is chosen from the group consisting of hydrogen, alkyl, aryl and substituted aryl; R<sup>6</sup> and R<sup>7</sup> are chosen from the group consisting of hydrogen, halogen and lower alkyl; D is -C(O) or -NHC(O)-;

Applicant Serial Number : Or et al. : 10/007,235

Filed

: October 22, 2001

Page

 $\mathbf{E}$ is chosen from the group consisting of C<sub>5</sub>-C<sub>8</sub> alkyl, heterocyclyl, substituted heterocyclyl, and NR<sup>10</sup>R<sup>11</sup>;

 $R^{10}$ is hydrogen or lower alkyl;

 $R^{11}$ is chosen from C<sub>1</sub>-C<sub>10</sub> hydrocarbon, substituted aryl and substituted alkyl; and


 $\mathbf{Y}$ is -O-, -S-, -NH- or a direct bond,

or a pharmaceutically acceptable salt thereof.

## Claims 2-10 (Canceled)



11. (Currently Amended) A compound according to claim 1 wherein phenyl or napthyl.





12. (Currently amended) A compound according to claim 11 wherein

wherein

- $\mathbb{R}^{12}$ is chosen from the group consisting of hydrogen, halogen, lower alkyl, hydroxy, lower alkoxy, nitro and [(lower alkoxy)carbonyl)] lower alkoxy;
- $R^{13}$ is chosen from the group consisting of hydrogen, halogen, lower alkyl, hydroxy and lower alkoxy;
- $R^{14}$ is chosen from the group consisting of hydrogen, halogen, lower alkyl, hydroxy and lower alkoxy; and

Applicant : Or et al. Serial Number : 10/007,235

Filed : October 22, 2001

Page : 5

c→ and d→ designate the points of attachment to the carbon chain and D respectively.

13. (Original) A compound according to claim 1 wherein D is -C(O)-.

Claims 14-15 (Canceled)

16. (Original) A compound according to claim 1 wherein R<sup>2</sup> is phenyl, ethyl, propyl, or butyl.

Claims 17-18 (Canceled)

- 19. (Withdrawn) A method of treating or preventing a protease precipitated disease which comprises administering to a mammal suffering from said disease or at risk to said disease a therapeutically effective amount of a compound according to claim 1.
- 20. (Withdrawn) A method according to claim 19 wherein said disease is HIV, AIDS, or a related condition.
- 21. (Withdrawn) A method according to claim 19 wherein said disease is malaria.
- 22. (Withdrawn) A method according to claim 19 wherein said disease is chosen from connective tissue disease, muscular dystrophy, breast cancer and Alzheimer's disease.
- 23. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof.
- 24. (Original) A pharmaceutical composition according to claim 23 comprising at least one additional antiviral agent.